Introduction: Primary granulocytic sarcoma of the breast is a rare and poor-prognosis malignancy. Clinicians do not have sufficient knowledge of this disease and often misdirect it as other soft tissue sarcomas or inflammation.
Introduction
Granulocytic sarcoma (GS) is a malignant neoplasm of myeloid origin that locates outside the bone marrow. The tumor is also being termed as chloroma, extraordinary myeloid tumor, or myeloid sarcoma (MS), which generally present with a green color due to the presence of myeloperoxidase (MPO). [1] The incidence of GS is only 2% to 14% of all acute myeloid leukemia cases. Granulocytic sarcoma can be developed in any area of the body, and the most common sites of GS are the bones, lymph nodes, soft tissues, and skin. [2, 3] But primary GS of the breast is rare, the clinical characteristics and diagnosis of which are typical and challenging. [4] [5] [6] Here, we report a case of GS in the breast without evidence of hematological features of myeloid malignancy in order to improve understanding of the disease further and provide a reference for standardized and individualized clinical treatments.
Case report
A 42-year-old Asian female hospitalized to our Hospital in November 17, 2017, with a self-discovered asymptomatic growing and palpable right breast mass that had been present for 4 months. Physical examinations showed a 2 cm Â 2 cm mass located in the lower outer quadrant, and a mobile swollen axillary lymph gland approximately 2 cm in diameter. Her blood routine reviews were as follows: WBC count was 8.09 Â 109/L (normal range, 3.5-9.5 Â109/L); with 76.6% neutrophils (normal range, 40-75%); 19.4% lymphocytes (normal range, 20-50%); 3.3% monocytes (normal range, 3-10%); 0.5% eosinophils (normal range, 0.7-8%); and 0.2% basophils (normal range, 0-1%). Her RBC count was 4.31 Â1012/L (normal range, 3.8-5.1 Â 1012/L); hemoglobin was 108 g/L (normal range, 110-150 g/L). And her platelet count was 219 Â109/L (normal range, 125-350 Â 109/L). Serum biochemical parameters were well within normal limits.
Ultrasound scan of the breast (Fig. 1 ) revealed a single, irregular, ill-defined margin hypothetic area measuring approximately 2 cm Â 1.8 cm, located in 8 o'clock positions, corresponding to the known palpable mass. On the right axillary presented a well-defined hypothesis lesion about 2 cm Â 0.7 cm, Editor: N/A. which could be considered to lymph node. Molybdenum target mammography ( Fig. 1 ) showed a mass without calcification, located in the outer quadrant. Breast magnetic resonance imaging (MRI) ( Fig. 2 ) showed an intumescent mass over the outer quadrant of the right breast coalesce with axillary lymph node. The lump was hyperactive on T1-weighted and T2-weighted images, suggesting malignancy. Dotted lesions were scattered all over bilateral breasts. The computed tomography (CT) scan revealed a proliferative inflammatory lesion at the right lung. Cardiac ultrasound reminded tricuspid regurgitation and left ventricular diastolic.
The patient accepted modified radical mastectomy in the right breast and sentinel lymph node biopsy (SLNB) at November 20, 2017. Intraoperative frozen section was diagnosed as invasive carcinoma. Paraffin section diagnosis is GS of the healthy breast, all lymph glands have no tumor involved. Immune-histochemical indicated ( Fig. 3 ): MPO(+), LCA(+), BCL-2(+), C-myc(+), ER(À), PR(À), cerbB2(À), CK5/6(À), ECad(À), CK(À), P120(À), CD20 (À), PAX5(À), CD3(À), CD5(À), BCL-6(À), CD10(À), MUM-1 Postoperatively, the patient received 2 cycles of IA regimen chemotherapy composed of inhibition and cytosine arabinoside. Then she started on HA regimen chemotherapy, which includes Homoharringtonine and cytosine arabinoside. Currently the woman achieved complete remission. We advised her to accept the bone marrow transplant. But the patient refused. The followup of this patient has no evidence of disease progression or spread during 1 year. In the future, the patient will receive ultrasound scan of the breast, chest X-ray and bone marrow aspirate and biopsy every 3 months.
Discussion
Granulocytic sarcoma (GS) is an uncommon extracellular tumor comprised of immature granulocytic cells. This type of malignancy frequently occurs during the course of active hematological disease, including acute or chronic leukemia and myeloproliferative disorder, or occurs during remission from leukemia. [7] [8] [9] [10] Granulocytic c sarcoma of the breast more often was found in patients with an established history of a myeloid leukemia. [11] Primary granulocytic sarcoma (PGS) of the breast without a relevant history of hematological abnormality, is rarely in clinical. [12] These tumors are usually clinically indistinguishable from other breast tumors. Patients with PGS of the breast, like in our case, most presented with a palpable mass that can be either painful or painless and involved in unilateral breast, but it also can involve in bilateral involvement. Some patients may have skin involvement and/ or enlarged axillary lymph nodes. However, patients usually exhibit no other associated symptoms, such as nipple retraction or discharge. [11, [13] [14] [15] The diagnosis of PGS in the breast is normally a challenge, and misdiagnosis is usually high. A third study of primary GS diagnosed by the MD Anderson Cancer Center reported that almost 75% patients were middle-aged. [16] Misdiagnosis may particularly occur in those poorly differentiated tumors and in patients whom presenting with isolated disease. The most common medications are as large-cell non-Hodgkin lymphoma, lymphoblastic lymphoma, undifferentiated carcinoma, lobular carcinoma of the breast (especially infiltrating lobular carcinoma), extraordinary hematopoiesis, and inflammation. [17] Therefore, how to differentiate lymph sarcoma is a difficult problem to be resolved clinically.
Imaging tests, including mammography and ultrasound, are sometimes difficult to distinguish GS from other similar tumors. [18] Due to the fact that it usually appears as a noncalcified low-echo lump with unequal size and boundary blur in imaging examination, GS is prone to be misdirected as a malignant breast tumor. [15, 19, 20] Magnetic resonance imaging (MRI) has the virtue of distinguishing benign and malignant tumors, but not for the diagnosis of GS. In this case, the t1-weighted image and the t2weighted image of the lesion tissue are displayed as a penetrating intensity tumor, suggesting a malignant tumor compared to the breast substance.
At present, the ability to get an accurate diagnosis of GS depends largely on the additional histological and immunohistochemically findings within the tumor. Immunohistochemistry, flow cytometry, fluorescence in situ hybridization, and other molecular techniques can improve the diagnostic accuracy. Many features can aid in proving the diagnosis, such as myeloperoxidase (MPO), CD34, CD43, CD117, and CD68. [16, 21] The immunohistochemical detection of MPO-positive cells is helpful to confirm the final diagnosis. The expression levels of MPOpositive cells in GS as reported by Mourad et al and Pileri et al were 66% and 83.6%, respectively. [4, 22] Cytokeratin staining may exclude an epithelial-based tumor and use of myeloid MPO staining would have suggested a hematologic tumor origin. Specific CD markers can also be handy, such as CD117 and CD68, CD43 is positive in most of the cases, and 75% are reactive for CD45. [23, 24] Negative B-and T-cell markers (CD45, CD20, UCHL-1, CD3, and CD30) would further exclude the Figure 3 . The pathological appearance of breast granulocytic sarcoma showed diffuse infiltration growth, most cells were large, the nucleus was vacuolated, the nucleoli were obvious, and a few cells were renal nuclei. A, Hematoxylin and eosin stain (magnification, Â400). B, Leukocyte common antigen (LCA) was decisive (magnification, Â400). C, Myeloperoxidase reactivity in tumor cells was strongly positive (magnification, Â400). diagnosis of lymphoma. Several genetic anomalies have been associated with GS, such as t (8; 21) and in (16) , which result in AML1/ETO (RUNX1/RUNX1T1) and CBF/MYH11 gene fusions respectively. [4, 25, 26] Account for the rarely rise of PGS in the breast, randomized controlled trials had been limited. Therapy for GS of breast is currently still in controversy. There is no definitive consensus regarding the optimal treatment of primary extracellular GS. However, most studies have concluded that all patients with GS should receive standard systemic chemotherapy followed by mastectomy or lumpectomy. [21, [26] [27] [28] Imrie et al [29] reported that the overall survival of chemotherapytreated patients was longer compared with those who did do not receive chemotherapy. In our case, patient received mastectomy and systemic chemotherapy, and there was not any local recurrence identified in the breast half a year later. From the above, GS in the breast tissue is rare. However, it still needs to be considered in the differential diagnosis of any tumor in the breast. As in our case, the patient has no systemic signs of the disease and the immunological examination is hard to distinguish GS from other tumors. Histology then plays an important part in the diagnosis. The optimal treatment for PGS is still controversial. A simple bacteriological diagnosis of GS is insufficient to decide systemic treatment strategies. The present studies pointed out that lumpectomy combined with systemic chemotherapy results in a good outcome for patients with GS of the breast. However, it is not the right most favorable treatment strategy for all GS patients. In the targeted treatment era, attempt should be made to define the chromosomal abnormality to guide treatment and stratify prognosis. Multicenter controlled trials are needed to further refine management decisions and investigate the role of novel targeted therapies.
